Hertility Health pulls in £4.2M in Seed funding as it sets eyes on becoming the UK’s leading ‘home for women’s health’
● The funding round was led by prolific seed investors LocalGlobe and Venrex, alongside key strategic angel investors
● The investment will be used to expand Hertility Health’s ability to provide accessible and tailored diagnostics in women’s health and next-generation advancements through at-home testing, as well as expand its current clinical trials aiming to reduce the diagnosis time for some of the most common conditions
Hertility Health, the new women’s health start-up revolutionising the world of hormone and reproductive health, today announces the closing of a £4.2 million Seed funding round led by LocalGlobe – one of the UK’s most prolific seed investors, Venrex, and some key angel investors including former CEO of Bupa, Evelyn Bourke, CEO of Nested and the unicorn company GoCardless, Matt Robinson.
The funds will help Hertility Health expand its current product offering of fertility and hormone testing, menopause, miscarriage, postnatal care, polycyctic ovarian syndrome (PCOS) and endometriosis testing, as well as aid the expansion of its current clinical trials which aim to reduce the diagnosis time for some of the most common reproductive conditions. This cash injection will also work towards establishing Hertility Health as the leading scientific and clinical educational health hub for women in a sector that’s set to be worth $50bn by 2025.
For far too long, women have been reactive when it comes to their fertility, only seeking answers once they think something is wrong. Hertility Health has already helped over 2,000 women understand their reproductive health and infertility risks, working with leading world experts to provide personalised care pathways that help with all aspects of women’s health, including symptom management, egg freezing and IVF. In recognising the sensitive nature of these results, Hertility Health also offers fertility counselling to those in need.
“We live in a society that expects us to tolerate pain and mask our symptoms. Some women spend over ten years on their contraception, never fully knowing if there might be something wrong”, says Hertility Health CEO and Founder, Dr Helen O’Neill. On average, 1 in 5 Hertility Health users have been found to have a previously undiagnosed reproductive condition which has been revealed as a result of testing with Hertility Health.
Hertility Health user, Emily Champion, said that her Hertilty Health journey was
“A life-changing experience. Quite literally. The fear of infertility is so very real. Why should we women have to fight so hard to get to the truth of our own bodies?! The answer is… we shouldn’t! Hertility Health has not only provided me with reassurance and hope but also have shown their loyalty by continuing my journey on a secondary care pathway. They too believe that our questions shouldn’t be left unanswered. These personable & inspirational individuals are rocking the boat for the health sector and I feel so privileged to have been a part of it. Through a simple blood test, I now know that I am fortunate enough to have a good egg count, not have PCOS and am on the road to diminishing my bloat! Thank you to the best team of experts!”
“The world class team of experts, scientists and researchers at Hertility Health are what make it a real game-changer in the industry”, said Julia Hawkins at LocalGlobe. “Together, we’re excited to help Hertility Health become the home for women’s health, building on its incredible success to date and meeting the clear consumer demand for an accessible, affordable, high-quality solution to reproductive health concerns and curiosity.”
The COVID-19 pandemic has caused a surge in demand for remote and accessible help. The current NHS guidelines stipulate women must prove they have been actively trying for over 12 months before being referred for specialist help (requiring them to be heterosexual), or to have had at least three miscarriages before being investigated. For the 1 in 7 couples who will experience infertility, this is simply not good enough. Of course there is the option to go private, but this can incur costs of up to £1,800 for a check – not exactly ‘accessible’ or ‘affordable’ – which Hertilty offers for a fraction of this cost.
Mark Esiri of Venrex Investment Management, commented:
“Venrex tries to find creative entrepreneurs who often have ‘differences of opinion’ with the status quo. This has been a common thread at companies we have been lucky enough to back, including Revolut, Charlotte Tilbury, Mumsnet, NotOnTheHighStreet and Maven Clinic. WE are very fortunate to be working with the Hertility Health team who are bringing world class technical expertise, a data-driven approach and relentless energy to address deeply important health issues. We believe that these bright and passionate founders can use their expertise to positively change the world.”
Founded by female scientists who felt passionate about the need for change, they built Hertility Health while on their maternity leave, dedicating themselves and their expertise to the mission. Hertility Health was born out of pure frustration for the lack of research into women’s health and the lack of support available to women who were curious or worried about their reproductive health.
Officially launching in 2020 during the pandemic, Hertility Health is addressing one of the biggest market segments in which there has been little advancement for many years.
For more information, please contact the team at [email protected]
Notes to Editors
About Hertility Health:
Hertility Health is a science-driven network of care created to give reproductive and hormone health the attention it needs. Hertility helps women get to the root of their symptoms effectively, by providing their community with tailored at-home testing, evidence-based medicine, and educational content. Hertility Health offers not just a test, but a triage system, and their services connect women with highly-rated licensed experts and clinics, providing them with a personalised care pathway. Results are then published onto a personalised online dashboard, offering insights into your ovarian reserve, menstrual cycle and ovulation, hormone health and crucially highlights any fertility red flags.
About Dr Helen O’Neill CEO, Founder
Dr O’Neill is a tenured Lecturer in University College London where she lectures in Reproductive and Molecular Genetics and leads her own research group as well as serving as Director of Reproductive Science and Women’s Health. She has an honours degree in Genetics, an MSc in Prenatal Genetics and Fetal Medicine from UCL and did her PhD and postdoctoral research on the genetics of ovarian development in the Department of Stem Cell Biology and Developmental Genetics at the National Institute for Medical Research.
She lectures both masters and medical students, the alumni of which are placed in senior research, clinical, IVF and pharmaceutical companies globally. As a thought-leader in reproductive science, she has been interviewed frequently on the BBC, BBC World News, Sky News, the Guardian and was awarded in the Top Twenty Women in Data, 2019.
About Dr Natalie Getreu, COO, Founder
Dr. Natalie Getreu is a global expert in ovarian biology with expertise in bringing scientific discovery to clinical practice. Dr Natalie established the first NHS funded ovarian tissue cryopreservation service which allows women facing cancer treatment to be able to preserve their fertility. In order to facilitate this, she both forged and fostered fundamental relations to enable the establishment of ethics board approval, biobanking and resource management for patient recruitment. Her instrumental contacts are far-reaching across the public national health system. Natalie holds a Masters Degree in Reproductive Science and Women’s Health and a PhD in Fertility Preservation from University College London (UCL) where her research focused on ovarian tissue freezing.
About Deirdre O’Neill, CCO, Founder
Deirdre is a dual-qualified lawyer in England and Ireland with a masters degree in Medical Law from King’s College London. Her Masters focussed on the global regulation of bio-sciences with particular regard to embryo research and gene therapy. Deirdre specialises and has worked in corporate law and venture capital for a number of years. Previously, Deirdre had been working in the VC and mergers and acquisitions team at Cooley LLP, acting both for investors and companies, in deals ranging from £100,000 to £150 million.